Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2026-01-07 Director's Dealing
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2026-01-07 English
3
Director's Dealing
2026-01-07 English
3
Director's Dealing
2026-01-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 5, 2026, for SAB Biotherapeutics, Inc. The key content is the appointment of two new directors to the Board of Directors, including detailed biographical information and the context of their appointment. The document specifically includes Item 5.02, which relates to the departure and appointment of directors or officers. There is no financial data or earnings information, nor is this a full annual or quarterly report. The document is not a proxy solicitation or voting results announcement. It is clearly an announcement of changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (9526 characters) supports that this is a substantive filing, not a brief announcement or report publication notice. Confidence is high given the clear content and SEC form type.
2026-01-07 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, debt securities, warrants, rights, and units. The document includes a base prospectus and an ATM prospectus for an at-the-market offering. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2025-12-30 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or corporate changes. The content describes the establishment of a new 'At the Market Offering' program and the termination of a prior similar program. It details the terms of the sales agreement with UBS Securities LLC and the termination of the previous agreement with Cantor Fitzgerald & Co. There are no financial statements or detailed financial analysis included, only an announcement of financing activity. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes. The document length is 5564 characters, sufficient to provide substantive details about the financing update rather than a brief notice. Therefore, the correct classification is CAP with high confidence.
2025-12-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.